Related Experiment Videos
[Docetaxel therapy against anthracycline resistant breast cancer]
S Oura1, T Sakurai, G Yoshimura
1Dept. of Surgery, Wakayama Medical College Kihoku Hospital.
Abstract:
To evaluate the efficacy of docetaxel therapy against anthracycline-resistant breast cancer, twenty patients were treated with docetaxel. Of the 20 patients pretreated with anthracycline, 17 were clinically anthracycline-resistant and the remaining three were refractory to anthracycline on histoculture drug response assay. Nine patients had loco-regional recurrence and 11 had distant +/- loco-regional recurrence. Docetaxel (49-60 mg/m2) was administered every 4 weeks, and was infused 1-13 times (median; 3 times). Of the 19 evaluable patients, eight (42%) showed partial response with the docetaxel therapy. Durations of the response ranged from 1 to 8 months (median; 4 months). Major adverse effects of the therapy were alopecia, neutropenia, and leucocytopenia. Hypersensitivity reaction was observed in one case. In addition, severe adverse effects such as grade 2 pneumonia and grade 4 diarrhea were found in one patient each. In conclusion, although the adverse effects are not negligible, docetaxel therapy is effective against anthracycline-resistant breast cancer.
Insights
Docetaxel shows efficacy in treating anthracycline-resistant breast cancer. This study found a 42% partial response rate in patients, despite manageable side effects like neutropenia and alopecia.
Area of Science:
- Oncology
- Pharmacology
Background:
- Breast cancer treatment often involves anthracyclines.
- Resistance to anthracyclines presents a significant clinical challenge.
- Identifying effective alternative therapies is crucial for patient outcomes.
Purpose of the Study:
- To assess the effectiveness of docetaxel in patients with anthracycline-resistant breast cancer.
- To document response rates and duration of response to docetaxel therapy.
- To identify and report adverse events associated with docetaxel treatment in this patient cohort.
Main Methods:
- Twenty patients with anthracycline-resistant breast cancer were enrolled.
- Docetaxel was administered at doses of 49-60 mg/m2 every 4 weeks.
- Patient responses and adverse events were closely monitored.
Main Results:
- Eight out of 19 evaluable patients (42%) achieved a partial response to docetaxel.
- The median duration of response was 4 months, ranging from 1 to 8 months.
- Common adverse effects included alopecia, neutropenia, and leucocytopenia; severe events were rare.
Conclusions:
- Docetaxel demonstrates significant efficacy as a treatment option for anthracycline-resistant breast cancer.
- While adverse effects are present, they are generally manageable.
- Docetaxel offers a viable therapeutic strategy for patients who have progressed on anthracycline-based chemotherapy.